Sputnik V developers have requested authorization for the emergency use of their vaccine against him Covid-19 in Pakistan, the Dawn newspaper writes this Friday, citing an official from the Pakistani Ministry of Health.
« Is a vaccine double dose to be administered with syringes, « he said. The official added that “in addition, the Chinese company Anhui Zheifi Longcom Biopharmaceuticals Company Limited has requested the phase III clinical trial of its vaccine in Pakistan. « This drug was developed in cooperation with the Institute of Microbiology of the Chinese Academy of Sciences.
The Pakistani drug regulator, Drap, has to date registered the vaccine of the Anglo-Swedish pharmaceutical AstraZeneca and that of the Chinese Sinopharm. Another Chinese company, CanSino Biologics, is conducting a phase III clinical trial of its vaccine in Pakistan.
Russia was the first in the world to approve in August 2020 the use of a vaccine against him Covid-19. The drug, developed by the Nikolai Gamaleya Center for Epidemiology and Microbiology, is marketed under the name Sputnik V and consists of two doses that are applied with an interval of 21 days. The first is based on human adenovirus type 26 and the second on recombinant human adenovirus type 5. According to clinical trials, the vaccine has shown an efficacy of more than 90 percent.
To date, the emergency use of Sputnik V has been authorized by Argentina, Algeria, Belarus, Bolivia, the United Arab Emirates, Hungary, Palestine, Paraguay, Serbia, Turkmenistan, and Venezuela.
Coronavirus in the world today: all the information
Coronavirus in Argentina: All the information about the pandemic throughout the country
Coronavirus vaccine: progress in the race to combat covid-19